Jan 21, 2003
Callisto Pharmaceuticals completes $5.86 million private placement

Jan 6, 2003
Callisto Pharmaceuticals granted orphan drug designation for ATIPRIMOD for multiple myeloma indication

Dec 12, 2003
Research presented on Callisto Pharmaceuticals' lead drug candidate for Multiple Myeloma

Dec 4, 2003
Callisto Pharmaceuticals Announces Appointment of Chairman of Scientific Advisory Board

Nov 25, 2003
Callisto Pharmaceuticals Presents Preclinical Findings on Its Lead Drug Candidate for Multiple Myeloma

Oct 21, 2003
Callisto Pharmaceuticals to Present at Rodman & Renshaw Techvest Healthcare Conference

Oct 21, 2003
Callisto Pharmaceuticals Announces Dr. Moshe Talpaz to Join Scientific Advisory Board

Oct 7, 2003
Callisto Pharmaceuticals Receives STTR/NIH Grant Award

September 24, 2003
Callisto Pharmaceuticals Announces Filing of IND on Atiprimod for Multiple Myeloma

September 16, 2003
Callisto scientist Dr. Kunwar Shailubhai, Executive Vice President and Head R&D, contributed an article on bioterrorism to the journal, Investigational Drugs, featuring research conducted at Callisto Pharmaceuticals. The article discusses current biodefense strategies of the National Institute of Allergy and Infectious Diseases (NIAID), and the technologies that are currently being developed in pharmaceutical companies to combat weapons of bioterrorism.

September 12, 2003
Callisto Pharmaceuticals, Inc. announced that Dr. Michael J. Zelefsky, a nationally and internationally recognized radiation oncologist and Chief of the Brachytherapy Service at Memorial Sloan Kettering Cancer Institute in New York, has become a member of its Board of Directors.

August 5, 2003
Callisto announced that Dr. Kenneth C. Anderson, Director of the Jerome Lipper Multiple Myeloma Center of the Dana-Farber Cancer Institute, and Professor of Medicine at Harvard Medical School will become a member of Callisto's Scientific Advisory Board. Dr. Anderson is a well recognized leader in multiple myeloma research and clinical drug development. "I am happy to join the Scientific Advisory Board and excited to see Callisto's drug candidate for multiple myeloma, Atiprimod, moving forward into clinical development" said Dr. Anderson.

July 21, 2003
Callisto announced the filing of two provisional patent applications covering the antiangiogenic properties of Atiprimod and azaspirane analogs. The antiangiogenic and anticancer activities of Atiprimod are being further evaluated under a Screening Agreement with the National Cancer Institute to evaluate Atiprimod in solid tumor animal models.

June 30, 2003
Callisto announced the appointment of new members of the Board of Directors and certain changes were made to management. The new Board of Directors comprises Gabriel M. Cerrone, the Acting Chairman of the Board, Christoph Bruening, lain Ross, Edwin Snape and Albert J. Henry. In addition, Gary S. Jacob, Ph.D. was appointed Acting Chief Executive Officer in addition to his duties as Chief Scientific Officer, Kunwar Shailubhai, Ph.D. was appointed Executive Vice President and Head of Research and Development, and Donald Picker, Ph.D. was appointed Vice President, Drug Development.

June 12, 2003
Callisto announced that the National Cancer Institute (NCI) will work with Callisto to further develop Atiprimod for additional cancer uses. Under a Screening Agreement, NCI will further examine Atiprimod in animal models of colon cancer and other solid tumor models. This research is to be funded completely by NCI.

May 28, 2003
Callisto Pharmaceuticals announced that it completed its planned change of corporate domicile from Florida to Delaware and change of corporate name from “Webtronics, Inc.” to “Callisto Pharmaceuticals, Inc.”

May 1, 2003
Webtronics, Inc. announced that its former parent Callisto Pharmaceuticals closed its merger with Synergy Pharmaceuticals. As a result of the merger, Callisto and Synergy became wholly-owned subsidiaries of Webtronics.

On Dec. 2002
Dr. John Zabriskie, head of Callisto’s superantigen technology, and emeritus Prof at the Rockefeller University, received a $1.1 million dollar USAMIRMC grant from the United States Army to develop biodefensive agents to protect against bioweapons that utilize Staphylococcus and Streptococcus microorganisms.

May 2002
Dr. Kunwar Shailubhai has found uroguanylin, a hormone produced in the intestinal tract and colon, may be an effective chemopreventative for colorectal cancer. This unique hormone helps replenish damaged cells in the lining of the colon - cells that may become cancerous, playing a key role in the critical process of programmed cell death. This delicate balance of cellular turnover within the colon lining is crucial to the prevention of cancer. Uroguanylin appears to help maintain this critical balance. In fact, in colon cancer tumors the hormone is deficient - an important discovery that may lead to an effective strategy for prevention. Uroguanylin may also be useful as an oral therapy to treat colorectal cancer.